There are currently 451 clinical trials in New Orleans, Louisiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Ochsner Clinic Foundation, Ochsner Medical Center Jefferson, Tulane University School of Medicine and University Medical Center New Orleans. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Transforming Care for Individuals with Childhood-onset Systemic Lupus Erythematosus
Recruiting
This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.
Gender:
ALL
Ages:
Between 12 years and 22 years
Trial Updated:
02/05/2025
Locations: Children's Hospital of New Orleans/ Tulane University, New Orleans, Louisiana
Conditions: Systemic Lupus Erythematosus of Childhood (Disorder)
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
Recruiting
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: Ochsner Clinic, New Orleans, Louisiana
Conditions: Mitral Valve Regurgitation
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
02/05/2025
Locations: Children's Hospital NOLA, New Orleans, Louisiana
Conditions: Severe Aplastic Anemia
Single Versus Dual Implant Fixation of Distal Femur Fractures
Recruiting
The goal of this clinical trial is to compare two types of surgical fixation in patients with specific kinds of distal femur fractures. The main questions it aims to answer is which operation for distal femur fractures is better for efficient return to work and everyday activities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Louisiana State University, New Orleans, Louisiana
Conditions: Articular Fractures
High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Recruiting
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researcher determine if hi... Read More
Gender:
MALE
Ages:
60 years and above
Trial Updated:
02/04/2025
Locations: Ochsner Medical Center Jefferson, New Orleans, Louisiana
Conditions: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Hybrid Type I Effectiveness-Implementation Trial of Project nGage
Recruiting
The goal of this Hybrid Type I effectiveness-implementation trial is to test Project nGage, an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black men and women ages 18-49.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/04/2025
Locations: Tulane University, New Orleans, Louisiana
Conditions: HIV Seropositivity
Burn Validation Study
Recruiting
The purpose of this study is to validate the algorithm for burn healing assessment by the Spectral MD DeepView device which would provide burn healing potential assessment.
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: University Medical Center, New Orleans, Louisiana
Conditions: Burns, Wound Heal, Wounds and Injuries
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
Recruiting
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for pur... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: Children's Hosp-New Orleans, New Orleans, Louisiana +1 locations
Conditions: Haemophilia A and B With and Without Inhibitors
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Recruiting
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: Crohn's Disease
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Recruiting
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Glioblastoma Multiforme
Evaluation of Young United Parents
Recruiting
The purpose of the study is to determine the impact of the offer to participate in the Young United Parents! (YUP!) intervention relative to the control condition on use of effective non-barrier contraception and frequency of vaginal sex without condoms three months after the intervention period has concluded.
Gender:
FEMALE
Ages:
Between 15 years and 20 years
Trial Updated:
01/30/2025
Locations: The Policy & Research Group, New Orleans, Louisiana
Conditions: Teen Pregnancy Prevention
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: Triple Negative Breast Cancer